- Home
- WKC vs XERS Comparison
WKC vs XERS Comparison
Compare WKC & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WKC | XERS |
|---|---|---|
| Founded | 1984 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | WKC | XERS |
|---|---|---|
| Price | $39.90 | $8.40 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $28.00 | $10.83 |
| AVG Volume (30 Days) | 1.3M | ★ 1.8M |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.96% | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | ★ 1.44 | 0.01 |
| Revenue | ★ $36,916,600,000.00 | $49,590,000.00 |
| Revenue This Year | $0.62 | $34.37 |
| Revenue Next Year | $3.42 | $22.86 |
| P/E Ratio | ★ $27.94 | $825.50 |
| Revenue Growth | N/A | ★ 142.67 |
| 52 Week Low | $22.21 | $4.87 |
| 52 Week High | $41.20 | $10.08 |
Technical Indicators
Market Signals| Indicator | WKC | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 75.61 | 56.04 |
| Support Level | $22.92 | $8.00 |
| Resistance Level | N/A | $8.42 |
| Average True Range (ATR) | 1.23 | 0.32 |
| MACD | 0.24 | -0.11 |
| Stochastic Oscillator | 72.52 | 31.50 |
Price Performance
Historical ComparisonAbout WKC World Kinect Corporation
World Kinect Corp is an energy management company involved in providing supply fulfillment, energy procurement advisory services, and transaction and payment management solutions to commercial and industrial customers. It sells and delivers liquid fuels, natural gas, electricity, renewable energy, and other sustainability solutions. The company operates in three reportable segments consisting of aviation, land, and marine. It earns the majority of its revenue from the Aviation segment.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.